Ascorbic Acid and Thiamine Effect in Septic Shock

Tae Gun Shin116 enrolled

Overview

The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.

Sepsis is a complex disease involving life-threatening organ dysfunction caused by a dysregulated host response to infection and is still associated with unacceptably high mortality. Sepsis management should be undertaken as a medical emergency and focused on timely intervention, including early identification and treatment of infection through appropriate antimicrobial therapy and source control when applicable as well as reversing hemodynamic instability through fluid resuscitation and vasopressor use if necessary. Despite these supportive therapies, morbidity and mortality have remained high, suggesting the need for adjuvant therapies for inflammatory and oxidative stress in patients with sepsis; however, no agents have been proven to definitely improve survival. Vitamin C plays a role in mediating inflammation through antioxidant activities and is also important as a cofactor/co-substrate for the synthesis of endogenous adrenaline, cortisol, and vasopressin. Recently, several clinical trials have reported the positive effects of vitamin C on outcomes in sepsis or septic shock. During sepsis, vitamin C prevents neutrophil-induced lipid oxidation and protects against the loss of the endothelial barrier. Early intravenous supplementation is therefore needed to limit loss of microcirculation and oxidation of lipids. Thiamine is also a key cofactor for glucose metabolism, the generation of ATP (adenosine triphosphate), and the production of NADPH. Considering acute consumption in the hypermetabolic state, thiamine supplementation might be a reasonable therapeutic adjunct for patients with sepsis and was added to reduce the risk of renal oxalate crystallization. These findings led to a recent before-and-after study showing that treatment of sepsis with a combination of vitamin C, hydrocortisone, and thiamine prevented organ dysfunction and reduced the mortality rate. The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

116

Conditions

Septic Shock Sepsis

Interventions

Combination therapy of vitamin C and thiamineDRUG

Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days

Normal saline solutionDRUG

Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days

Eligibility

Sex: ALLMin age: 19 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adult patients (\> 18 years) 2. Septic shock: sepsis with persisting hypotension requiring vasopressors to maintain a mean arterial pressure ≥65 mm Hg and a serum lactate level \>2 mmol/L despite adequate volume resuscitation. Sepsis is defined as clinically suspected or confirmed infection with acute organ failure identified as an acute change in total SOFA score with 2 points or more. Exclusion Criteria: 1. Transferred patients from other hospitals after application of vasopressors or mechanical ventilation 2. Patients who signed a "Do not attempt resuscitation" order or who had set limitations on invasive care 3. Patients who have a terminal, unresponsive illness and survival discharge is not expected (metastatic terminal cancer, etc.) 4. Patients who experienced cardiac arrest before enrollment or when death is anticipated within 24 hours despite maximal treatment 5. Patients who take more than 1g of Vitamin C per day before enrollment or who take supplemental thiamine 6. Pregnant woman 7. Known Glucose-6-phosphate dehydrogenase deficiency 8. Patients with a history of hypersensitivity to vitamin C or thiamine 9. Known Mediterranean anemia 10. Known hyperoxaluria 11. Known cystinuria 12. Acute gout attack 13. Known oxalate renal stone 14. Patients who meet the inclusion criteria 24 hours after emergency department arrival or when enrollment is delayed more than 24 hours after diagnosis of septic shock 15. Inability or refusal of a subject or legal surrogate to give informed consent

Locations (6)

Department of Emergency Medicine, Seoul National University Bundang Hospital,

Seongnam-si, Gyeonggi-do, South Korea

Department of Emergency Medicine, Borame Medical Center, Seoul National University, College of Medicine

Seoul, South Korea

Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,

Seoul, South Korea

Outcomes

Primary Outcomes

Delta Sequential Organ Failure Assessment (SOFA) score

72-hour change in SOFA score, which reflected recovery from organ failure (delta SOFA = SOFA at enrollment - SOFA after 72 hours)

Time frame: Enrollment to 72 hours

Secondary Outcomes

28-day mortality

The number of participants who did not survive until Day 28 will be compared between the treatment and the control group

Time frame: Day 28

7-day mortality (early death)

The number of participants who did not survive until Day 7 will be compared between the treatment and the control group

Time frame: Day 7

90-day mortality

The number of participants who did not survive until Day 90 will be compared between the treatment and the control group

Time frame: Day 90

Time to death

Days until death

Time frame: Enrollment to Day 28

In-hospital death

The number of participants who did not survive at hospital discharge will be compared between the treatment and the control group

Time frame: Up to 12 weeks

Intensive care unit death (ICU) death

The number of participants who did not survive at ICU discharge from the first index ICU admission will be compared between the treatment and the control group

Time frame: Up to 12 weeks

Time to Shock reversal

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.